Why Is EYEPOINT INC (EYPT) Stock Moving Today?

Why EYPT stock is moving today

EYPT stock is moving sharply lower today, down 69% to $4.07 in pre-market trading, following the release of topline results from its Phase 3 LUGANO trial for Duravyu. The primary driver of the decline is the announcement that the primary endpoint of best-corrected visual acuity (BCVA) was not met in the full dataset. The drug was also found to be non-inferior to aflibercept only in an ad hoc analysis that excluded a 4% asymmetric cohort of patients who experienced vision loss unrelated to wet AMD.

What Happened

EyePoint Inc. disclosed the results of its LUGANO trial, the first of two pivotal Phase 3 studies for Duravyu in treating wet age-related macular degeneration (AMD). The trial showed that Duravyu reduced treatment burden by 42% and demonstrated strong durability and favorable safety. However, the primary BCVA endpoint was not met in the full dataset. In an ad hoc analysis excluding a 4% asymmetric cohort, the drug was non-inferior to aflibercept, with a nominal p-value of 0.0096. The 8-K filing on August 17 confirmed the trial results and outlined the financial details. The stock opened with a 56.3% gap down from the prior close of $14.75 and has since traded as low as $3.50.

What The Data Shows

The stock’s intraday session has been highly volatile, with a low of $3.50 and a high of $6.90, and volume has surged to 5.2 million shares, or 4.3 times the 3-month average. The stock has moved from $12.25 to $14.75 over the last 8 sessions before today’s drop. The 52-week tape showed 23 fresh 52-week highs on August 17, highlighting recent strength before the trial results. A single unusual put option print of $391K has also been recorded in the last 36 hours. The CEO of EyePoint has not made any recent transactions, and the only insider trade in the last 90 days was a $73K sale by the Chief Medical Officer on June 30.

What To Watch

EyePoint has no scheduled earnings date in the near term. Investors should monitor coverage breadth and potential follow-up analyses of the LUGANO trial results, as well as any further corporate actions or regulatory updates.